DOMICILIARY AZACITIDINE: A NEW EXPERIENCE IN OUR CENTER
(Abstract release date: 05/19/16)
EHA Library. Herráez Balanzat I. 06/09/16; 134831; PB1931
Mrs. Inés Herráez Balanzat
Contributions
Contributions
Abstract
Abstract: PB1931
Type: Publication Only
Background
Azacitidine is an antineoplastic agent used in adults with no indication of bone marrow transplantation and with a diagnosis of intermediated-2 or high risk myelodisplastic syndrome (MDS), high risk chronic myelomonocytic leukemia (CMML) or myeloid acute leukemia (AML).
Aims
Show the experience of using domiciliary Azacitidine and to evaluate its effectiveness in a third level hospital.Evaluate the patient’s satisfaction.Estimate the efficiency of the treatment.
Methods
Retrospective observational study including patients who have received treatment with domiciliary Azacitidine from June 2015 to January 2016. The following variables were chosen: gender, age, base pathology, treatment cycles, secondary effects, readmissions, Exitus and satisfaction.Domiciliary hospitalization unit (DH), trains patients and their families and monitors vital signs during the treatment.We have revised the official cost for one-day stay in an adult day hospital (ADH) versus domiciliary administration according to the July 2014 issue of “BOIB”.Telephone surveys were conducted (table 1), asking patients and their families (with a score from 0 to 10), to evaluate the quality of the service.
Results
We have nine patients, six male and three female, between the ages 54-84. The treatment cycles at home vary between 1 and 8. We had no readmissions during the treatment. Three adverse effects appeared: itching, cutaneous reaction and asthenia.Of the nine patients, two died due to disease progression.We compared the costs for one treatment cycle: at the ADH the cost was 3,850 Euros (550 Euros a day for seven days) with the costs of the same treatment at home, which was 2,037 Euros (291 Euros a day for 7 days). If we calculate all the 34 cycles received, the costs would be 130,900 Euros for receiving the drug at the hospital, versus 69,258 Euros at home. In 7 months that we conducted the domiciliary program, the hospital saved 61,642 Euros.The telephone survey showed that 100% of the questions were answered with the maximum score.
Conclusion
There were no readmissions during the treatment and the secondary effects were minor, so we conclude that home administration is safe.All patients had a high level of satisfaction and experienced an improvement in their quality of life.The treatment with Azacitidine in DH has the same effectiveness and more efficiency than in ADH.
Session topic: E-poster
Keyword(s): AML, MDS
Type: Publication Only
Background
Azacitidine is an antineoplastic agent used in adults with no indication of bone marrow transplantation and with a diagnosis of intermediated-2 or high risk myelodisplastic syndrome (MDS), high risk chronic myelomonocytic leukemia (CMML) or myeloid acute leukemia (AML).
Aims
Show the experience of using domiciliary Azacitidine and to evaluate its effectiveness in a third level hospital.Evaluate the patient’s satisfaction.Estimate the efficiency of the treatment.
Methods
Retrospective observational study including patients who have received treatment with domiciliary Azacitidine from June 2015 to January 2016. The following variables were chosen: gender, age, base pathology, treatment cycles, secondary effects, readmissions, Exitus and satisfaction.Domiciliary hospitalization unit (DH), trains patients and their families and monitors vital signs during the treatment.We have revised the official cost for one-day stay in an adult day hospital (ADH) versus domiciliary administration according to the July 2014 issue of “BOIB”.Telephone surveys were conducted (table 1), asking patients and their families (with a score from 0 to 10), to evaluate the quality of the service.
Results
We have nine patients, six male and three female, between the ages 54-84. The treatment cycles at home vary between 1 and 8. We had no readmissions during the treatment. Three adverse effects appeared: itching, cutaneous reaction and asthenia.Of the nine patients, two died due to disease progression.We compared the costs for one treatment cycle: at the ADH the cost was 3,850 Euros (550 Euros a day for seven days) with the costs of the same treatment at home, which was 2,037 Euros (291 Euros a day for 7 days). If we calculate all the 34 cycles received, the costs would be 130,900 Euros for receiving the drug at the hospital, versus 69,258 Euros at home. In 7 months that we conducted the domiciliary program, the hospital saved 61,642 Euros.The telephone survey showed that 100% of the questions were answered with the maximum score.
Conclusion
There were no readmissions during the treatment and the secondary effects were minor, so we conclude that home administration is safe.All patients had a high level of satisfaction and experienced an improvement in their quality of life.The treatment with Azacitidine in DH has the same effectiveness and more efficiency than in ADH.
Session topic: E-poster
Keyword(s): AML, MDS
Abstract: PB1931
Type: Publication Only
Background
Azacitidine is an antineoplastic agent used in adults with no indication of bone marrow transplantation and with a diagnosis of intermediated-2 or high risk myelodisplastic syndrome (MDS), high risk chronic myelomonocytic leukemia (CMML) or myeloid acute leukemia (AML).
Aims
Show the experience of using domiciliary Azacitidine and to evaluate its effectiveness in a third level hospital.Evaluate the patient’s satisfaction.Estimate the efficiency of the treatment.
Methods
Retrospective observational study including patients who have received treatment with domiciliary Azacitidine from June 2015 to January 2016. The following variables were chosen: gender, age, base pathology, treatment cycles, secondary effects, readmissions, Exitus and satisfaction.Domiciliary hospitalization unit (DH), trains patients and their families and monitors vital signs during the treatment.We have revised the official cost for one-day stay in an adult day hospital (ADH) versus domiciliary administration according to the July 2014 issue of “BOIB”.Telephone surveys were conducted (table 1), asking patients and their families (with a score from 0 to 10), to evaluate the quality of the service.
Results
We have nine patients, six male and three female, between the ages 54-84. The treatment cycles at home vary between 1 and 8. We had no readmissions during the treatment. Three adverse effects appeared: itching, cutaneous reaction and asthenia.Of the nine patients, two died due to disease progression.We compared the costs for one treatment cycle: at the ADH the cost was 3,850 Euros (550 Euros a day for seven days) with the costs of the same treatment at home, which was 2,037 Euros (291 Euros a day for 7 days). If we calculate all the 34 cycles received, the costs would be 130,900 Euros for receiving the drug at the hospital, versus 69,258 Euros at home. In 7 months that we conducted the domiciliary program, the hospital saved 61,642 Euros.The telephone survey showed that 100% of the questions were answered with the maximum score.
Conclusion
There were no readmissions during the treatment and the secondary effects were minor, so we conclude that home administration is safe.All patients had a high level of satisfaction and experienced an improvement in their quality of life.The treatment with Azacitidine in DH has the same effectiveness and more efficiency than in ADH.
Session topic: E-poster
Keyword(s): AML, MDS
Type: Publication Only
Background
Azacitidine is an antineoplastic agent used in adults with no indication of bone marrow transplantation and with a diagnosis of intermediated-2 or high risk myelodisplastic syndrome (MDS), high risk chronic myelomonocytic leukemia (CMML) or myeloid acute leukemia (AML).
Aims
Show the experience of using domiciliary Azacitidine and to evaluate its effectiveness in a third level hospital.Evaluate the patient’s satisfaction.Estimate the efficiency of the treatment.
Methods
Retrospective observational study including patients who have received treatment with domiciliary Azacitidine from June 2015 to January 2016. The following variables were chosen: gender, age, base pathology, treatment cycles, secondary effects, readmissions, Exitus and satisfaction.Domiciliary hospitalization unit (DH), trains patients and their families and monitors vital signs during the treatment.We have revised the official cost for one-day stay in an adult day hospital (ADH) versus domiciliary administration according to the July 2014 issue of “BOIB”.Telephone surveys were conducted (table 1), asking patients and their families (with a score from 0 to 10), to evaluate the quality of the service.
Results
We have nine patients, six male and three female, between the ages 54-84. The treatment cycles at home vary between 1 and 8. We had no readmissions during the treatment. Three adverse effects appeared: itching, cutaneous reaction and asthenia.Of the nine patients, two died due to disease progression.We compared the costs for one treatment cycle: at the ADH the cost was 3,850 Euros (550 Euros a day for seven days) with the costs of the same treatment at home, which was 2,037 Euros (291 Euros a day for 7 days). If we calculate all the 34 cycles received, the costs would be 130,900 Euros for receiving the drug at the hospital, versus 69,258 Euros at home. In 7 months that we conducted the domiciliary program, the hospital saved 61,642 Euros.The telephone survey showed that 100% of the questions were answered with the maximum score.
Conclusion
There were no readmissions during the treatment and the secondary effects were minor, so we conclude that home administration is safe.All patients had a high level of satisfaction and experienced an improvement in their quality of life.The treatment with Azacitidine in DH has the same effectiveness and more efficiency than in ADH.
Session topic: E-poster
Keyword(s): AML, MDS
{{ help_message }}
{{filter}}